Epigenetic Aging Clocks Predict Health Outcomes in HIV Patients on Treatment
Blood-based aging biomarkers successfully predict serious health events in people with well-controlled HIV infection over 10 years.
Summary
Researchers followed 216 people with HIV on suppressive therapy for 10 years, using blood tests to measure epigenetic aging markers. These molecular clocks, particularly GrimAge and PC-GrimAge, successfully predicted who would develop serious health problems. People with accelerated epigenetic aging had 2-4 times higher risk of non-AIDS complications, cancer, and death. All 17 participants who died had elevated DunedinPACE values above 1. This suggests epigenetic clocks could help doctors identify HIV patients at highest risk for age-related diseases, enabling earlier interventions.
Detailed Summary
This groundbreaking study demonstrates that epigenetic aging biomarkers can predict long-term health outcomes in people with HIV, potentially revolutionizing personalized care for this population.
Researchers analyzed blood samples from 216 HIV patients with sustained viral suppression, tracking eight different epigenetic clocks over a median 6.5 years of follow-up. These molecular aging markers measure how fast cells are aging at the DNA level, independent of chronological age.
Over 10 years, 105 participants experienced significant health events including 65 serious non-AIDS events, 96 aging-related conditions, and 17 deaths. The GrimAge and PC-GrimAge clocks emerged as the strongest predictors, with accelerated aging associated with 2-4 fold increased risks of serious complications, cancer, and mortality. Remarkably, every person who died had a DunedinPACE value above 1.
These findings suggest that despite effective HIV treatment, some patients experience accelerated biological aging that predisposes them to premature health decline. Epigenetic clocks could identify these high-risk individuals years before symptoms appear, enabling targeted interventions like enhanced monitoring, lifestyle modifications, or anti-aging therapies. This represents a major advance toward precision medicine in HIV care, moving beyond viral suppression to optimize long-term healthspan.
Key Findings
- GrimAge epigenetic clock predicted 2-4 fold higher risk of serious non-AIDS events
- All 17 deaths occurred in patients with DunedinPACE values above 1
- Horvath clock associated with 50% increased risk of aging-related events
- PC-GrimAge and PhenoAge predicted increased non-AIDS cancer risk
Methodology
Longitudinal observational study of 216 HIV patients with sustained viral suppression, followed for median 6.5 years. Baseline blood DNA methylation assessed using eight epigenetic clocks and principal component derivatives.
Study Limitations
Preliminary study with relatively small sample size requiring validation in larger cohorts. Limited to well-controlled HIV patients, so generalizability to other populations unclear.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.